Clinical Trial Detail

NCT ID NCT02542293
Title Study of 1st Line Therapy Study of MEDI4736 With Tremelimumab Versus SoC in Non Small-Cell Lung Cancer (NSCLC) (NEPTUNE).
Recruitment Active, not recruiting
Gender both
Phase Phase III
Variant Requirements yes
Sponsors AstraZeneca

non-small cell lung carcinoma


Gemcitabine + Cisplatin

Carboplatin + Gemcitabine

Durvalumab + Tremelimumab

Paclitaxel + Carboplatin

Cisplatin + Pemetrexed

Carboplatin + Pemetrexed

Age Groups: adult

Additional content available in CKB BOOST